Literature DB >> 9121184

Malignant melanoma: prognostic indicators.

I Ahmed1.   

Abstract

The incidence of cutaneous malignant melanoma in the Caucasian population has continued to increase at an alarming rate and is expected to be 1 in 75 by the year 2000. Within the medical community, these trends have prompted an interest in factors that potentially influence the biologic activity of such lesions. Several clinical and pathologic variables have been identified that affect the progression and behavior of melanoma. On the basis of multivariate analysis, the most important factors for predicting survival in patients with stage I and II melanomas are tumor thickness, presence of ulceration, and anatomic site of the primary tumor (the prognosis is poorer with head and neck lesions than with extremity lesions). For patients with stage III melanomas, all the foregoing factors plus the extent of nodal disease are of prognostic importance. For patients with stage IV melanomas, the main prognostic factors are the number of metastatic lesions and the site of metastatic involvement (visceral lesions portend a poor outcome).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121184     DOI: 10.4065/72.4.356

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

1.  Met amplification and tumor progression in Cdkn2a-deficient melanocytes.

Authors:  Matthew W Vanbrocklin; James P Robinson; Todd Whitwam; Adam R Guilbeault; Julie Koeman; Pamela J Swiatek; George F Vande Woude; Joseph D Khoury; Sheri L Holmen
Journal:  Pigment Cell Melanoma Res       Date:  2009-04-29       Impact factor: 4.693

2.  Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.

Authors:  Matthew W VanBrocklin; James P Robinson; Kristin J Lastwika; Joseph D Khoury; Sheri L Holmen
Journal:  Pigment Cell Melanoma Res       Date:  2010-04-23       Impact factor: 4.693

3.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

4.  Pancreatic resection for metastatic melanoma.

Authors:  M Nikfarjam; P Evans; C Christophi
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

Review 5.  Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma.

Authors:  Andrea J McKinney; Sheri L Holmen
Journal:  Chin J Cancer       Date:  2011-03

6.  Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial.

Authors:  Arwa Ali; Monica Dumbrava; Kylie Riddell; Nina Stewart; Robyn Ward; Ahmed K Ibrahim; Melvin Chin
Journal:  BMC Cancer       Date:  2020-04-22       Impact factor: 4.430

7.  Differential Gene Expression and Methylation Analysis of Melanoma in TCGA Database to Further Study the Expression Pattern of KYNU in Melanoma.

Authors:  Min Wang; Meng Liu; Yingjian Huang; Ziyang Wang; Yuqian Wang; Ke He; Ruimin Bai; Tingyi Ying; Yan Zheng
Journal:  J Pers Med       Date:  2022-07-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.